Intradermal needle-free vaccine against Mycoplasma hyopneumoniae and PCV2, all in one, in suspension for injection For the active immunisation of pigs: - to reduce lung lesions associated with porcine enzootic pneumonia caused by Mycoplasma hyopneumoniae. Also, to reduce the incidence of these lesions (as observed in field studies). - to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by Porcine circovirus type 2 PCV2. Efficacy against PCV2 genotypes a, b and d has been demonstrated in field studies. - to reduce culling rate and the loss of daily weight gain caused by Mycoplasma hyopneumoniae and/or PCV2 related diseases (as observed at 6 months of age in field studies). Mycoplasma hyopneumoniae: Onset of immunity: 3 weeks after vaccination. Duration of immunity: 23 weeks after vaccination. Porcine circovirus type 2: Onset of immunity: 2 weeks after vaccination. Duration of immunity: 22 weeks after vaccination. In addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of PCV2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION: For intradermal use. Administer one dose of 0.2 ml to pigs from 3 weeks of age onwards by intradermal administration at the sides of the neck using a suitable needle-free device able to administer 0.2 ml doses per shot (with an injection stream diameter of 0.25-0.30 mm and a peak force of injection of 0.9-1.3 N).
